Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biocon in Talks With Bayer for Drug Development (India)

This article was originally published in PharmAsia News

Executive Summary

Bayer AG Chairman Werner Wenning met with leaders of Biocon, an Indian biotech firm, last week in Bangalore to discuss co-development of innovative biotech drugs. "We are considering options to develop products together. Biocon had world class research and development (R&D) centers with excellent facilities. As of now, we have not yet signed any cooperation agreement," Wenning said. Major firms such as Bayer are increasingly looking at new ways to share the expenses and risks involved in new drug development. UTI Securities senior analyst Surjit Pal notes the development "is an opportunity for Indian companies, which do not yet have the financial muscle to take new drugs to the market on their own." Biocon currently has four new biotech drugs in the pipeline, targeted at diabetes, cardiovascular diseases, and inflammation. Bayer has three production and formulations plants in India, and is also in discussions with other players for a possible joint venture or acquisition. (Click here for more

You may also be interested in...

The Future Of Purdue: Will The ‘Public Benefit Corporation’ Model Take Off?

Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a public benefit company could have far-reaching significance for the industry – if it ever gets off the ground.

Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs

Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.

COVID Vaccines: Is Expanded Access A Better Option Than Emergency Use Authorization?

Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts